120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
肥胖 2 型糖尿病患者血清维生素 D 水平与二甲双胍疗效的关联：一项基于 HbA1c 降幅的回顾性队列研究
Authors Wang Y, Liu H, Li Y, Wnag X, He C, Wei Z
Received 3 September 2025
Accepted for publication 13 January 2026
Published 13 February 2026 Volume 2026:22 565034
DOI https://doi.org/10.2147/TCRM.S565034
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sandeep Ajoy Saha
Yimeng Wang, Hongli Liu, Yijia Li, Xiaoxue Wang, Chen He, Zhi Wei
Endocrinology Department, Hanzhong Central Hospital, Hanzhong, People’s Republic of China
Correspondence: Zhi Wei, Endocrinology Department, Hanzhong Central Hospital, No. 557, Middle West Labor Road, Hantai District, Hanzhong City, Shaanxi Province, 723000, People’s Republic of China, Email wally19890123@126.com
Purpose: To investigate the association between baseline serum 25-hydroxyvitamin D [25(OH)D] levels and glycemic response to metformin monotherapy in obese adults with type 2 diabetes mellitus (T2DM).
Patients and Methods: This single-center retrospective cohort study analyzed the electronic medical records (January 2021–December 2023) of obese T2DM patients initiating metformin monotherapy. Participants were stratified by baseline 25(OH)D levels: deficiency (< 20 ng/mL, n = 256) or sufficiency (≥ 20 ng/mL, n = 171). Propensity score matching (1:1) balanced covariates (age, sex, BMI, HbA1c, diabetes duration, comorbidities, season), yielding 142 matched pairs (n = 284). The primary outcome was absolute HbA1c reduction (ΔHbA1c) at 3 months. Multivariable linear regression, subgroup, and sensitivity analyses were performed.
Results: In the matched cohort, vitamin D-sufficient patients achieved a clinically meaningful and statistically significant greater HbA1c reduction versus vitamin D-deficient patients (mean difference: 0.34%; 95% CI: 0.16– 0.52%; p < 0.001). Baseline 25(OH)D positively correlated with ΔHbA1c (r = 0.32, p < 0.001). Multivariable regression confirmed that vitamin D sufficiency independently predicted greater ΔHbA1c (adjusted β = 0.41%, 95% CI: 0.22– 0.60%, p < 0.001). Subgroup analyses revealed enhanced effects in females (p-interaction = 0.018), patients > 60 years (β = 0.49% vs ≤ 60 years 0.33%, p-interaction = 0.009), and baseline HbA1c ≥ 8.5% (β = 0.56% vs < 8.5% 0.21%, p-interaction = 0.003). Adverse events were comparable between groups.
Conclusion: Higher baseline vitamin D levels (≥ 20 ng/mL) are associated with significantly improved metformin efficacy in obese T2DM patients, particularly among females, older adults, and those with poorer glycemic control. Vitamin D status may serve as a predictive biomarker for metformin response.
Plain Language Summary: Why was this Study Done?
Many people with type 2 diabetes also have low vitamin D levels, especially if they are living with obesity. Vitamin D helps the body use insulin properly. Metformin is a common diabetes medicine, but it does not work the same for everyone. We wanted to determine whether having enough vitamin D helps metformin work better.
What did the Researchers do?
We looked back at health records of 427 obese adults with type 2 diabetes who started taking metformin alone. We split them into two groups: those with low vitamin D (less than 20 ng/mL) and those with enough vitamin D (20 ng/mL or more). We compared how much their blood sugar levels (HbA1c) improved after three months.
What did the Researchers Find?
People with enough vitamin D had a significantly greater improvement in blood sugar levels than those with low vitamin D. This effect was especially strong in women, people over 60, and those with higher starting blood sugar levels. Vitamin D levels were positively correlated with a better response to metformin. Side effects were similar in both groups.
What do these Results Mean?
Having enough vitamin D may help metformin work better in people with type 2 diabetes and obesity. Checking vitamin D levels when starting metformin could help doctors predict how well the treatment will work. Future studies should test whether giving vitamin D supplements can actually improve diabetes control in those who are deficient.
Keywords: vitamin D, metformin, HbA1c, obesity, type 2 diabetes, biomarker
Endocrinology Department, Hanzhong Central Hospital, Hanzhong, People’s Republic of China
Correspondence: Zhi Wei, Endocrinology Department, Hanzhong Central Hospital, No. 557, Middle West Labor Road, Hantai District, Hanzhong City, Shaanxi Province, 723000, People’s Republic of China, Email wally19890123@126.com
Purpose: To investigate the association between baseline serum 25-hydroxyvitamin D [25(OH)D] levels and glycemic response to metformin monotherapy in obese adults with type 2 diabetes mellitus (T2DM).
Patients and Methods: This single-center retrospective cohort study analyzed the electronic medical records (January 2021–December 2023) of obese T2DM patients initiating metformin monotherapy. Participants were stratified by baseline 25(OH)D levels: deficiency (< 20 ng/mL, n = 256) or sufficiency (≥ 20 ng/mL, n = 171). Propensity score matching (1:1) balanced covariates (age, sex, BMI, HbA1c, diabetes duration, comorbidities, season), yielding 142 matched pairs (n = 284). The primary outcome was absolute HbA1c reduction (ΔHbA1c) at 3 months. Multivariable linear regression, subgroup, and sensitivity analyses were performed.
Results: In the matched cohort, vitamin D-sufficient patients achieved a clinically meaningful and statistically significant greater HbA1c reduction versus vitamin D-deficient patients (mean difference: 0.34%; 95% CI: 0.16– 0.52%; p < 0.001). Baseline 25(OH)D positively correlated with ΔHbA1c (r = 0.32, p < 0.001). Multivariable regression confirmed that vitamin D sufficiency independently predicted greater ΔHbA1c (adjusted β = 0.41%, 95% CI: 0.22– 0.60%, p < 0.001). Subgroup analyses revealed enhanced effects in females (p-interaction = 0.018), patients > 60 years (β = 0.49% vs ≤ 60 years 0.33%, p-interaction = 0.009), and baseline HbA1c ≥ 8.5% (β = 0.56% vs < 8.5% 0.21%, p-interaction = 0.003). Adverse events were comparable between groups.
Conclusion: Higher baseline vitamin D levels (≥ 20 ng/mL) are associated with significantly improved metformin efficacy in obese T2DM patients, particularly among females, older adults, and those with poorer glycemic control. Vitamin D status may serve as a predictive biomarker for metformin response.
Plain Language Summary: Why was this Study Done?
Many people with type 2 diabetes also have low vitamin D levels, especially if they are living with obesity. Vitamin D helps the body use insulin properly. Metformin is a common diabetes medicine, but it does not work the same for everyone. We wanted to determine whether having enough vitamin D helps metformin work better.
What did the Researchers do?
We looked back at health records of 427 obese adults with type 2 diabetes who started taking metformin alone. We split them into two groups: those with low vitamin D (less than 20 ng/mL) and those with enough vitamin D (20 ng/mL or more). We compared how much their blood sugar levels (HbA1c) improved after three months.
What did the Researchers Find?
People with enough vitamin D had a significantly greater improvement in blood sugar levels than those with low vitamin D. This effect was especially strong in women, people over 60, and those with higher starting blood sugar levels. Vitamin D levels were positively correlated with a better response to metformin. Side effects were similar in both groups.
What do these Results Mean?
Having enough vitamin D may help metformin work better in people with type 2 diabetes and obesity. Checking vitamin D levels when starting metformin could help doctors predict how well the treatment will work. Future studies should test whether giving vitamin D supplements can actually improve diabetes control in those who are deficient.
Keywords: vitamin D, metformin, HbA1c, obesity, type 2 diabetes, biomarker